doxo-emch and phytochlorin

doxo-emch has been researched along with phytochlorin* in 1 studies

Other Studies

1 other study(ies) available for doxo-emch and phytochlorin

Article	Year
Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy. Advanced materials (Deerfield Beach, Fla.), 2021, Volume: 33, Issue:7 Extracellular vesicles (EVs) hold great potential in both disease treatment and drug delivery. However, accurate drug release from EVs, as well as the spontaneous treatment effect cooperation of EVs and drugs at target tissues, is still challenging. Here, an engineered self-activatable photo-EV for synergistic trimodal anticancer therapy is reported. M1 macrophage-derived EVs (M1 EVs) are simultaneously loaded with bis[2,4,5-trichloro-6-(pentyloxycarbonyl) phenyl] oxalate (CPPO), chlorin e6 (Ce6), and prodrug aldoxorubicin (Dox-EMCH). After administration, the as-prepared system actively targets tumor cells because of the tumor-homing capability of M1 EVs, wherein M1 EVs repolarize M2 to M1 macrophages, which not only display immunotherapy effects but also produce H Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chlorophyllides; Combined Modality Therapy; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Extracellular Vesicles; Female; Humans; Hydrazones; Immunotherapy; Macrophages; Male; Mice; Oxalates; Photochemical Processes; Photochemotherapy; Photosensitizing Agents; Porphyrins; Singlet Oxygen	2021

Article

Year

Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy.

Advanced materials (Deerfield Beach, Fla.), 2021, Volume: 33, Issue:7

Extracellular vesicles (EVs) hold great potential in both disease treatment and drug delivery. However, accurate drug release from EVs, as well as the spontaneous treatment effect cooperation of EVs and drugs at target tissues, is still challenging. Here, an engineered self-activatable photo-EV for synergistic trimodal anticancer therapy is reported. M1 macrophage-derived EVs (M1 EVs) are simultaneously loaded with bis[2,4,5-trichloro-6-(pentyloxycarbonyl) phenyl] oxalate (CPPO), chlorin e6 (Ce6), and prodrug aldoxorubicin (Dox-EMCH). After administration, the as-prepared system actively targets tumor cells because of the tumor-homing capability of M1 EVs, wherein M1 EVs repolarize M2 to M1 macrophages, which not only display immunotherapy effects but also produce H

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chlorophyllides; Combined Modality Therapy; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Extracellular Vesicles; Female; Humans; Hydrazones; Immunotherapy; Macrophages; Male; Mice; Oxalates; Photochemical Processes; Photochemotherapy; Photosensitizing Agents; Porphyrins; Singlet Oxygen

2021